M&A / Deals Eli Lilly doubles down on in vivo with $7bn Kelonia buyout Pharmaceutical TechnologyLilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.M&A / DealsGene Therapy PlatformRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Technology Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company’s chance of success. M&A / DealsGene Therapy PlatformRead full story Post navigation Previous: Asahi Kasei acquires German company AicurisNext: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026